PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Patients' Preferences for Adjuvant or Neoadjuvant Chemotherapy in Breast Cancer
European Institute of Oncology
450 participants
Jun 4, 2021
OBSERVATIONAL
Conditions
Summary
The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment. The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value. The analyses will be conducted into three different groups of patients to value the survival benefit expected: 1. before to start the chemotherapy 2. during chemotherapy 3. after the end of chemotherapy
Eligibility
Inclusion Criteria4
- Patients with early or locally advanced breast cancer
- Patients candidate to adjuvant/neoadjuvant chemotherapy or patients who are receiving adjuvant/neoadjuvant chemotherapy or patients who received adjuvant/neoadjuvant chemotherapy
- Sufficient literacy in Italian to complete the questionnaires
- Patients must provide signed, written or advanced electronic signature (AES or AdES), informed consent
Exclusion Criteria1
- None
Interventions
Completion of questionnaires at the time of study entry
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06332976